Primary clear cell adenocarcinoma of prostate: A diagnostic challenge

Che-Wei Chang; Hsin-Ling Yin; Ching-Chia Li

doi:10.4103/UA.UA_187_20

Primary clear cell adenocarcinoma of prostate: A diagnostic challenge

Urol Ann. 2021 Oct-Dec;13(4):434-437. doi: 10.4103/UA.UA_187_20. Epub 2021 Sep 2.

Authors

Che-Wei Chang^{1

2

3}, Hsin-Ling Yin⁴, Ching-Chia Li^{2

3

5}

Affiliations

¹ Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
² Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
³ Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁴ Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
⁵ Department of Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Abstract

Clear cell adenocarcinoma (CCA) rarely occurs in men, not to mention in prostate. We reported a 44-year-old male patient who suffered from recurrent dysuria and frequency for 6 months. Transurethral resection of the prostate was performed to relieve bladder outlet obstruction. However, CCA of the prostate was confirmed through pathological examination. A thorough checkup was performed to distinguish it from metastatic clear cell carcinoma from other primary origins. Currently, no consensus for the treatment of CCA of the prostate has been reached. After discussing with the patient, he decided to receive immunotherapy with pembrolizumab. Herein, we reported this rare case of CCA in the prostate.

Keywords: Clear cell adenocarcinoma; immunotherapy; prostate.

Publication types

Case Reports